SMT202400013T1 - Cellule t car contro bcma per il trattamento di mieloma multiplo - Google Patents

Cellule t car contro bcma per il trattamento di mieloma multiplo

Info

Publication number
SMT202400013T1
SMT202400013T1 SM20240013T SMT202400013T SMT202400013T1 SM T202400013 T1 SMT202400013 T1 SM T202400013T1 SM 20240013 T SM20240013 T SM 20240013T SM T202400013 T SMT202400013 T SM T202400013T SM T202400013 T1 SMT202400013 T1 SM T202400013T1
Authority
SM
San Marino
Prior art keywords
car
treatment
multiple myeloma
cells against
against bcma
Prior art date
Application number
SM20240013T
Other languages
English (en)
Italian (it)
Inventor
Antonio Beatriz Martín
Ispizua Álvaro Urbano
Amill Lorena Pérez
Rodriguez Guillermo Suñe
Otero Manel Juan
Original Assignee
Univ Barcelona
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap
Hospital Clinic Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Barcelona, Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap, Hospital Clinic Barcelona filed Critical Univ Barcelona
Publication of SMT202400013T1 publication Critical patent/SMT202400013T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
SM20240013T 2019-08-02 2020-08-03 Cellule t car contro bcma per il trattamento di mieloma multiplo SMT202400013T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382673 2019-08-02
EP20757544.0A EP4007777B1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma
PCT/EP2020/071831 WO2021023721A1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
SMT202400013T1 true SMT202400013T1 (it) 2024-03-13

Family

ID=67658496

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240013T SMT202400013T1 (it) 2019-08-02 2020-08-03 Cellule t car contro bcma per il trattamento di mieloma multiplo

Country Status (18)

Country Link
US (1) US12509525B2 (https=)
EP (2) EP4272837A3 (https=)
JP (1) JP7729561B2 (https=)
AU (1) AU2020325690A1 (https=)
CA (1) CA3148930A1 (https=)
DK (1) DK4007777T5 (https=)
ES (1) ES2971033T3 (https=)
FI (1) FI4007777T3 (https=)
HR (1) HRP20240037T1 (https=)
HU (1) HUE064890T2 (https=)
LT (1) LT4007777T (https=)
PL (1) PL4007777T3 (https=)
PT (1) PT4007777T (https=)
RS (1) RS65094B1 (https=)
SI (1) SI4007777T1 (https=)
SM (1) SMT202400013T1 (https=)
WO (1) WO2021023721A1 (https=)
ZA (1) ZA202201166B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021397A (ko) * 2022-02-09 2025-02-12 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 면역 관련 질환을 표적으로 하는 항-bcma car, 조성물 및 이의 방법
EP4378953A1 (en) * 2022-12-02 2024-06-05 Universitat de Barcelona Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2025141187A1 (en) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
NO3051026T3 (https=) 2011-10-21 2018-07-28
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
ES2953362T3 (es) 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Also Published As

Publication number Publication date
US20220267459A1 (en) 2022-08-25
AU2020325690A1 (en) 2022-03-03
ZA202201166B (en) 2022-10-26
DK4007777T5 (da) 2024-08-05
DK4007777T3 (da) 2024-01-15
PL4007777T3 (pl) 2024-03-11
SI4007777T1 (sl) 2024-03-29
JP7729561B2 (ja) 2025-08-26
EP4272837A3 (en) 2024-02-28
FI4007777T3 (fi) 2024-01-11
CA3148930A1 (en) 2021-02-11
US12509525B2 (en) 2025-12-30
EP4272837A2 (en) 2023-11-08
EP4007777A1 (en) 2022-06-08
WO2021023721A1 (en) 2021-02-11
HUE064890T2 (hu) 2024-04-28
HRP20240037T1 (hr) 2024-03-29
RS65094B1 (sr) 2024-02-29
JP2022542443A (ja) 2022-10-03
PT4007777T (pt) 2024-01-12
ES2971033T3 (es) 2024-06-03
LT4007777T (lt) 2024-02-12
EP4007777B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
IL287222A (en) bicyclic compounds
IL282984A (en) bicyclic compounds
ZA202006610B (en) Compositions for the treatment of skin conditions
ZA202007055B (en) Compositions for the treatment of skin conditions
IL286000A (en) Asketamine for the treatment of depression
ZA202201166B (en) Car t-cells against bcma for the treatment of multiple myeloma
HUE061444T2 (hu) Készítmények a magas vérnyomás kezelésére
IL277281B (en) Combined products for the treatment of respiratory syncytial virus
PL3877402T3 (pl) Leczenie skojarzone nadciśnienia tętniczego
EP3860618C0 (en) Compositions for the treatment of tauopathy
IL291221A (en) Methods for the synthesis of wolbenzine
PL3823655T3 (pl) Kompozycje do leczenia wulwodynii
IL318120A (en) Heterocyclic compounds for the treatment of epilepsy
NO20190133A1 (en) Fremgangsmåte for inspeksjon av rør
IL283885A (en) cxcr7 inhibitors for cancer therapy
ZA202006591B (en) Compositions for the treatment of hypertension
SI3921257T1 (sl) Postrojenje za obdelavo karoserije
IL290319A (en) Compound for combined treatment
HK40066186A (en) Car t-cells for the treatment of cd1a-positive cancer
GB201901130D0 (en) Formulation for the treatment of tendinopathies
GB201919095D0 (en) Inhibitory compounds
GB201917603D0 (en) Inhibitory compounds
GB201912603D0 (en) Inhibitory compounds
GB201904848D0 (en) Inhibitory compounds
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies